Pegvisomant

Pegvisomant

Klinički podaci
AHFS/Drugs.com	Monografija
Identifikatori
CAS broj	218620-50-9
ATC kod	H01AX01
DrugBank	DB00082
ChEMBL[1]	CHEMBL1201515 Y
Hemijski podaci
Formula	C990H1532N262O300S7
Mol. masa	22129,0 g/mol
Fizički podaci
Tačka topljenja	76 °C (169 °F)
Farmakokinetički podaci
Poluvreme eliminacije	~6 dana
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	Subkutano

Pegvisomant (Somavert) je antagonist receptora hormona rasta koji se koristi u tretmanu akromegalije.^[2][3][4]

1. ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
2. ↑ Schreiber, I; Buchfelder M, Droste M et al. (January 2007). „Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study”. European Journal of Endocrinology 156 (1): 75–82. DOI:10.1530/eje.1.02312. PMID 17218728. 
3. ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.  edit
4. ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.  edit